Media coverage about Chemed (NYSE:CHE) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chemed earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.4054786568482 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research cut Chemed from a “buy” rating to a “hold” rating in a report on Wednesday, June 20th. Royal Bank of Canada lifted their target price on Chemed to $321.00 and gave the stock a “market perform” rating in a report on Monday, July 30th. Finally, ValuEngine cut Chemed from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $315.33.
Shares of CHE stock opened at $313.54 on Friday. Chemed has a 12-month low of $186.09 and a 12-month high of $335.99. The company has a current ratio of 1.04, a quick ratio of 1.01 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $5.08 billion, a PE ratio of 58.50, a PEG ratio of 2.86 and a beta of 1.15.
Chemed (NYSE:CHE) last issued its earnings results on Wednesday, July 25th. The company reported $2.81 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.77 by $0.04. Chemed had a return on equity of 33.57% and a net margin of 11.00%. The firm had revenue of $441.80 million for the quarter, compared to analysts’ expectations of $434.28 million. During the same period in the previous year, the firm posted $2.15 earnings per share. The business’s revenue was up 6.4% compared to the same quarter last year. analysts predict that Chemed will post 11.05 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, August 31st. Stockholders of record on Monday, August 13th were issued a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 0.38%. This is a boost from Chemed’s previous quarterly dividend of $0.28. The ex-dividend date of this dividend was Friday, August 10th. Chemed’s payout ratio is 22.39%.
In other Chemed news, Director Donald E. Saunders sold 300 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $319.22, for a total transaction of $95,766.00. Following the sale, the director now directly owns 8,701 shares of the company’s stock, valued at $2,777,533.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin J. Mcnamara sold 19,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 19th. The stock was sold at an average price of $322.27, for a total value of $6,123,130.00. Following the sale, the insider now directly owns 124,491 shares in the company, valued at $40,119,714.57. The disclosure for this sale can be found here. Insiders sold 25,256 shares of company stock worth $8,127,168 over the last ninety days. Insiders own 4.90% of the company’s stock.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Recommended Story: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.